Levetiracetam Keppra in the dyskinesias induced from levodopa in patients with disease of Parkinson. Clinical study pilot in open, with farmacokinetic-farmacodynamic monitoring of the effects.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-002208-40-IT

Enrollment

Registered

2006-02-07

Start date

2005-06-14

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of the induced coreiche dyskinesias from the therapy with levodopa in patients with Disease of Parkinson. MedDRA version: 6.1 Level: PT Classification code 10028035

Interventions

Trade Name: KEPPRA 20 CPR RIV. 500 MG Pharmaceutical Form: Tablet INN or Proposed INN: Levetiracetam Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026